135 related articles for article (PubMed ID: 7666099)
1. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
[TBL] [Abstract][Full Text] [Related]
3. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
[TBL] [Abstract][Full Text] [Related]
6. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
Bierman PJ; Vose JM; Leichner PK; Quadri SM; Armitage JO; Klein JL; Abrams RA; Dicke KA; Vriesendorp HM
J Clin Oncol; 1993 Apr; 11(4):698-703. PubMed ID: 8478663
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
[TBL] [Abstract][Full Text] [Related]
8. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
Vriesendorp HM; Morton JD; Quadri SM
Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
Vriesendorp HM; Quadri SM
Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
[TBL] [Abstract][Full Text] [Related]
10. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
Vriesendorp HM; Quadri SM; Wyllie CT; Lai J; Borchardt PE; Harris L; Wucher R; Askew E; Schweichler L
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3324s-3329s. PubMed ID: 10541381
[TBL] [Abstract][Full Text] [Related]
11. Selection of reagents for human radioimmunotherapy.
Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
[TBL] [Abstract][Full Text] [Related]
12. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
[TBL] [Abstract][Full Text] [Related]
13. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
14. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
15. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease.
Lenhard RE; Order SE; Spunberg JJ; Asbell SO; Leibel SA
J Clin Oncol; 1985 Oct; 3(10):1296-300. PubMed ID: 4045523
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
[TBL] [Abstract][Full Text] [Related]
17. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
18. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
[TBL] [Abstract][Full Text] [Related]
19. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
Order SE
Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]